Nebivolol 2

ApprovedSmall molecule

FForest Laboratories

Nebivolol 2 is one of 51 small molecule programs targeting Impaired glucose tolerance. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Impaired Glucose ToleranceActive, not recruiting

HypertensionActive, not recruiting

Impaired Glucose ToleranceApproved

Active, not recruiting

HypertensionPhase 3

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

Nebivolol 2

FForest Laboratories

Approved

2 2

Edarbi

Takeda

Preclinical

10 3

Apresoline

Novartis

Preclinical

7 4

Benicar

Novartis

Preclinical

7 5

Zebeta

Teva

Preclinical

6 6

Edarbi

Takeda

Preclinical

4 7

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 8

Alphagan

AbbVie

Preclinical

—9

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 10

Disalcid

JJoslin Diabetes Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypertension2 trials

Efficacy and Safety Study to Evaluate Combination Therapy With Nebivolol and Lisinopril vs. Placebo and Monotherapy in Patients With Stage 2 Diastolic Hypertension

Completed·FForest Laboratories·Phase 4·NCT01218100·664 enrolled

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

Completed·FForest Laboratories·Phase 3·NCT01508026·4,161 enrolled

Impaired glucose tolerance1 trial

The Blood Pressure and Metabolic Effects of Nebivolol in Hypertensive Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose

Completed·FForest Laboratories·Phase 4·NCT00673790·537 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Nebivolol 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nebivolol 2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nebivolol 2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Forest Laboratories company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: FForest Laboratories

Nebivolol 2

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypertension2 trials

Impaired glucose tolerance1 trial

References

Drug Info

Quick Facts

Related News